Sunitinib-sensitive suicidal erythrocyte death

Cellular Physiology and Biochemistry

Volumn 30, Issue 3, 2012, Pages 512-522

  Shaik, Nazneen ^a   Lupescu, Adrian ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell volume; Eryptosis; Erythrocytes; Phosphatidylserine; Red blood cells; Sunitinib

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CERAMIDE; ENZYME INHIBITOR; HEMOGLOBIN; LIPOCORTIN 5; LUCIFERASE; LUCIFERIN; PHOSPHATIDYLSERINE; SUNITINIB;

ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL VOLUME; CYTOSOL; DRUG EXPOSURE; DRUG SENSITIVITY; ERYTHROCYTE; EXTRACELLULAR CALCIUM; FLUORESCENCE; HEMOLYSIS; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

EID: 84863875401     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341434     Document Type: Article

References (96)

1. Escudier B: Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:305-317.
2. Gravalos C, Grande E, Gasent JM: The potential role of sunitinib in gastrointestinal cancers other than GIST. Crit Rev Oncol Hematol 2010;76:36-43.
3. Heng DY, Kollmannsberger C: Sunitinib. Recent Results Cancer Res 2010;184:71-82.
4. Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT: Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Invest New Drugs 2011;29:1123-1131.
5. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H: The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006;5:2522-2530.
6. Mena AC, Pulido EG, Guillen-Ponce C: Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010;21 Suppl 1:S3-11.
7. Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E: Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Expert Opin Drug Metab Toxicol 2010;6:1005-1015.
8. Tanaka Y, Shibata MA, Morimoto J, Otsuki Y: Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Anticancer Res 2011;31:1225-1234.
9. Awasthi N, Schwarz MA, Schwarz RE: Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011;13:597-604.
10. Canter D, Kutikov A, Golovine K, Makhov P, Simhan J, Uzzo RG, Kolenko VM: Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol 2011;18:5819-5825.
11. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
12. Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC: Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets 2009;9:738-747.
13. Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC: Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Curr Cancer Drug Targets 2011;11:944-953.
14. Ping G, Hui-Min W, Wei-Min W, Bao-Hui H: Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population. Med Oncol 2011;28:578-583.
15. Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, Kawakami Y, Shimano H, Hara H, Takekoshi K: Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6Kl pathways through modulation of Bcl-2and BAD. Am J Physiol Endocrinol Metab 2012;302:E615-E625.
16. Vishnu P, Colon-Otero G, Kennedy GT, Marlow LA, Kennedy WP, Wu KJ, Santoso JT, Copland JA: RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. Gynecol Oncol 2012;124:589-597.
17. Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Vails J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Marti RM: Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. Int J Cancer 2012;130:967-978.
18. Zhang HP, Takayama K, Su B, Jiao XD, Li R, Wang JJ: Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiât Res (Tokyo) 2011;52:1-8.
19. Cohen JD, Babiarz JE, Abrams RM, Guo L, Kameoka S, Chiao E, Taunton J, Kolaja KL: Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol Appl Pharmacol 2011;257:74-83.
20. Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, Foller M: Eryptosis, a window to systemic disease. Cell Physiol Biochem 2008;22:373-380.
21. 2+ leak of human erythrocytes. Cell Physiol Biochem 2008;21:183-192.
22. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, Schulz E, Munzel T, Lang F: Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J 2009;23:1072-1080.
23. Kaestner L, Bernhardt I: Ion channels in the human red blood cell membrane: their further investigation and physiological relevance. Bioelectrochemistry 2002;55:71-74.
24. 2+ influx in human red blood cells. Bioelectrochemistry 2004;62:127-133.
25. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993;92:520-526.
26. Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM: Cation channels trigger apoptotic death of erythrocytes. Cell Death Differ 2003;10:249-256.
27. Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, Schulze-Osthoff K, WesselborgS: Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ 2001;8:1197-1206.
28. Lang F, Gulbins E, Lang PA, Zappulla D, Foller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 2010;26:21-28.
29. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F: Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol 2006;290:C244-C253.
30. Bhavsar SK, Bobbala D, Xuan NT, Foller M, Lang F: Stimulation of suicidal erythrocyte death by alpha-lipoic acid. Cell Physiol Biochem 2010;26:859-868.
31. Foller M, Huber SM, Lang F: Erythrocyte programmed cell death. IUBMB Life 2008;60:661-668.
32. Foller M, Mahmud H, Gu S, Wang K, Floride E, Kucherenko Y, Luik S, Laufer S, Lang F: Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death. J Physiol Pharmacol 2009;60:135-143.
33. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB-and PEG-coated gold nanorods on the induction of eryptosis/ erythroptosis in human erythrocytes. Nanotoxicology 2011; [Epub ahead of print]
34. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2011; [Epub ahead of print]
35. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK Activation and Function following Osmotic Shock of Erythrocytes. Cell Physiol Biochem 2011;28:1279-1286.
36. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, Thunemann M, Hofmann F, Schuier B, Vogel J, Pichler B, Kasinathan RS, Nicolay JP, Huber SM, Lang F, Feil R: Anemia and splenomegaly in cGKI-deficient mice. Proc Natl Acad Sei U S A 2008;105:6771-6776.
37. Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F: Protein Kinase CKlalpha Regulates Erythrocyte Survival. Cell Physiol Biochem 2012;29:171-180.
38. Bhavsar SK, Gu S, Bobbala D, Lang F: Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem 2011;27:547-556.
39. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9:412-423.
40. Motzer RJ, Hoosen S, Bello CL, Christensen JG: Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006;15:553-561.
41. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M: Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 2009;404:134-139.
42. Karbowski M: Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis. Adv Exp Med Biol 2010;687:131-142.
43. Kitazumi I, Tsukahara M: Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J 2011;278:427-441.
44. Martinou JC, Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011;21:92-101.
45. Rogalinska M: Alterations in cell nuclei during apoptosis. Cell Mol Biol Lett 2002;7:995-1018.
46. Starr DA, Fridolfsson HN: Interactions between nuclei and the cytoskeleton are mediated by SUN-KASH nuclear-envelope bridges. Annu Rev Cell Dev Biol 2010;26:421-444.
47. Brand VB, Sandu CD, Duranton C, Tanneur V, Lang KS, Huber SM, Lang F: Dependence of Plasmodium falciparum in vitro growth on the cation permeability of the human host erythrocyte. Cell Physiol Biochem 2003;13:347-356.
48. Bookchin RM, Ortiz OE, Lew VL: Activation of calcium-dependent potassium channels in deoxygenated sickledred cells. Prog Clin Biol Res 1987;240:193-200.
49. Bratosin D, Estaquier J, Petit F, Arnoult D, Quatannens B, Tissier JP, Slomianny C, Sartiaux C, Alonso C, Huart JJ, Montreuil J, Ameisen JC: Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ 2001;8:1143-1156.
50. Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004;11:231-243.
51. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010;26:9-20.
52. Dhami R, He X, Schuchman EH: Acid sphingomyelinase deficiency attenuates bleomycin-induced lung inflammation and fibrosis in mice. Cell Physiol Biochem 2010;26:749-760.
53. Becker KA, Grassme H, Zhang Y, Gulbins E: Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell Physiol Biochem 2010;26:57-66.
54. Kuebler WM, Yang Y, Samapati R, Uhlig S: Vascular barrier regulation by PAF, ceramide, caveolae, and NO-an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem 2010;26:29-40.
55. Li X, Becker KA, Zhang Y: Ceramide in redox signaling and cardiovascular diseases. Cell Physiol Biochem 2010;26:41-48.
56. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
57. Walter S, Fassbender K: Spingolipids in Multiple Sclerosis. Cell Physiol Biochem 2010;26:49-56.
58. Arboleda G, Huang TJ, Waters C, Verkhratsky A, Fernyhough P, Gibson RM: Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci 2007;25:3030-3038.
59. de la Monte SM: Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-481.
60. Tong M, Neusner A, Longato L, Lawton M, Wands JR, de la Monte SM: Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis 2009;17:827-844.
61. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH: Inhibiting glycosphingolipid synthesis improves glycémie control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 2007;56:1210-1218.
62. Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, Raz I, Han Y: Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 2009;296:E72-E78.
63. Holland WL, Summers SA: Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381-402.
64. Felder KM, Hoelzle K, Ritzmann M, Kilchling T, Schiele D, Heinritzi K, Groebel K, Hoelzle LE: Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Cell Physiol Biochem 2011;27:557-564.
65. Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupee R, Rodemann HP, Ghoreschi K, Rocken M, Schaller M, Lang F, Wieder T: The NFkB Pathway Inhibitors Bay 11-7082 and Parthenolide Induce Programmed Cell Death in Anucleated Erythrocytes. Cell Physiol Biochem 2011;27:45-54.
66. Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F: Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem 2011;28:347-354.
67. Nguyen DB, Wagner-Britz L, Maia S, Steffen P, Wagner C, Kaestner L, Bernhardt I: Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol Biochem 2011;28:847-856.
68. 2+ -permeable Cation Channels Triggering Erythrocyte Cell Membrane Scrambling. Cell Physiol Biochem 2011;28:857-864.
69. Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K, Lang F: Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cell Physiol Biochem 2011;28:339-346.
70. Bhavsar SK, Eberhard M, Bobbala D, Lang F: Monensin induced suicidal erythrocyte death. Cell Physiol Biochem 2010;25:745-752.
71. Braun M, Foller M, Gulbins E, Lang F: Eryptosis triggered by bismuth. Biometais 2009;22:453-460.
72. Eberhard M, Ferlinz K, Alizzi K, Cacciato PM, Faggio C, Foller M, Lang F: FTY720-induced suicidal erythrocyte death. Cell Physiol Biochem 2010;26:761-766.
73. Bernhardt I, Weiss E, Robinson HC, Wilkins R, Bennekou P: Differential effect of HOE642 on two separate monovalent cation transporters in the human red cell membrane. Cell Physiol Biochem 2007;20:601-606.
74. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
75. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232.
76. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol 2003;14:2750-2757.
77. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Ulbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med 2006;84:378-388.
78. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Götz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med 2007;85:273-281.
79. Lang PA, Kasinathan RS, Brand VB, Duranton C, Lang C, Koka S, Shumilina E, Kempe DS, Tanneur V, Akel A, Lang KS, Foller M, Kun JF, Kremsner PG, Wesselborg S, Laufer S, Clemen CS, Herr C, Noegel AA, Wieder T, Gulbins E, Lang F, Huber SM: Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem 2009;24:415-428.
80. Siraskar B, Ballal A, Bobbala D, Foller M, Lang F: Effect of amphotericin B on parasitemia and survival of Plasmodium berghei-infected mice. Cell Physiol Biochem 2010;26:347-354.
81. Bobbala D, Alesutan I, Foller M, Huber SM, Lang F: Effect of anandamide in Plasmodium Berghei-infected mice. Cell Physiol Biochem 2010;26:355-362.
82. Foller M, Bobbala D, Koka S, Huber SM, Gulbins E, Lang F: Suicide for survival-death of infected erythrocytes as a hostmechanism to survive malaria. Cell Physiol Biochem 2009;24:133-140.
83. Koka S, Bobbala D, Lang C, Boini KM, Huber SM, Lang F: Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2009;23:191-198.
84. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006;20:368-370.
85. Birka C, Lang PA, Kempe DS, Hoefling L, Tanneur V, Duranton C, Nammi S, Henke G, Myssina S, Krikov M, Huber SM, Wieder T, Lang F: Enhanced susceptibility to erythrocyte .,apoptosis" following phosphate depletion. Pflugers Arch 2004;448:471-477.
86. Zappulla D: Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to C02 increases? J Cardiometab Syndr 2008;3:30-34.
87. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
88. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vase Biol 2007;27:414-421.
89. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sei 2005;62:971-988.
90. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012;302:C644-651.
91. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
92. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
93. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
94. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996;88:1873-1880.
95. Kaestner L, Tabellion W, Lipp P, Bernhardt I: Prostaglandin E2 activates channel-mediated calcium entry in human erythrocytes: an indication for a blood clot formation supporting process. Thromb Haemost 2004;92:1269-1272.
96. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-2285.